Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
Juan E. Grunwald(University of Pennsylvania), Daniel Martín(Townsville Hospital), Stephanie A. Hagstrom(Cleveland Eye Clinic), Gui‐Shuang Ying(Philadelphia College of Osteopathic Medicine), Cynthia A. Toth(Duke University), Glenn J. Jaffe(Duke University), Maureen G. Maguire(Penn Presbyterian Medical Center), Jiayan Huang(University of Pennsylvania), Michael L. Klein(Oregon Health & Science University), Stuart L. Fine(University of Colorado Denver), Alison Martin(Cleveland Clinic), Barbara Blodi(University of Wisconsin–Madison), Ebenezer Daniel(University of Pennsylvania)
Cited by 585
Related Papers
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
|Ophthalmology|2012|1.7k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|857
Diabetic Retinopathy Preferred Practice Pattern®
|Ophthalmology|2019|703
Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
|Ophthalmology|2016|702
Adalimumab in Patients with Active Noninfectious Uveitis
|New England Journal of Medicine|2016|646